Pioneering Neurotherapeutics
Malia is a preclinical therapy discovery platform dedicated to revolutionizing the treatment of the central and peripheral nervous system. With a strong focus on the identification and creation of new bioactive compounds related to mechanisms involved in neurological conditions, our mission is to develop groundbreaking solutions for the prevention and remediation of neurodegenerative processes.
At Malia, we specialize in the identification and development of highly innovative products capable of altering the course of neurological decay. Our primary focus areas include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, and cognitive decline associated with aging.
Urgent and growing need for effective treatments
$51.2 b
2023 global market size for treatments focused on neurodegenerative conditions
+88%
projected growth over the next 10 years
Our Development Process
1— Target Prioritization:
We prioritize biological targets based on thorough analysis, considering genetic validation data and existing research in the field.
2— Translational Evaluation:
We assess the translatability of in vitro and in vivo assays for models of interest, ensuring alignment with our target objectives.
3— Asset Identification and Selection:
Through rigorous evaluation, we identify and prioritize biological assets and small molecules with potential interactions with selected targets. We integrate various techniques to ensure safety and efficacy before moving forward.
4—Collaboration and Integration:
We actively engage with partners specializing in data science and AI to maximize the success of our assets, leveraging cutting-edge technology and expertise.
5— Assay Execution:
We conduct detailed assays as per our evaluation, ensuring comprehensive understanding and validation of our chosen targets.
6— Safety Assessment:
The safety of our assets is paramount. We conduct thorough safety assessments for the selected assets, prioritizing the well-being of potential users.
7— Patent Submission and Collaboration:
We protect our innovations by submitting patents covering our developed assets. Additionally, we explore licensing and co-development opportunities with leading pharmaceutical companies to bring our products to market effectively.
Working Together to Save Lives
Malia is proud to announce that it has partnered with the American biotechnology company Kaliko to research and develop the next generation of neurotherapeutics. Together, we combine our expertise and resources to develop and commercialize groundbreaking neurotherapeutics. This collaboration underscores our commitment to address unmet medical needs and meaningfully impact the life of people around the world.